Abbv-181: Clinical Trials

7 trials of Abbv-181, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

5 active not recruiting, 1 recruiting, 1 terminated. 7 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	7	Active not recruiting 5, Recruiting 1, Terminated 1
Phase 3	2	Active not recruiting 2
Phase 1	1	Recruiting 1

Follow Abbv-181: new trials by email Literature Review of Abbv-181 trials Research Report on Abbv-181

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab - Non Small Cell Lung Carcinoma, c-MET	Phase 1 / Phase 2	Recruiting	AbbVie	252	2025-03-06	2026-10-27
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) Livmoniplimab, Budigalimab, Docetaxel - Urothelial Carcinoma	Phase 2	Active not recruiting	AbbVie	150	2025-01-20	2025-08-11
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Telisotuzumab Adizutecan, Budigalimab, Fluorouracil - Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Active not recruiting	AbbVie	185	2024-12-13	2026-07-21
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Livmoniplimab, Budigalimab, Pembrolizumab - Non-Small Cell Lung Cancer	Phase 2 / Phase 3	Active not recruiting	AbbVie	167	2024-04-10	2026-10-19
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) Livmoniplimab, Budigalimab, Durvalumab - Hepatocellular Carcinoma	Phase 2 / Phase 3	Active not recruiting	AbbVie	89	2024-01-11	2026-09-22
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 Budigalimab, Placebo for Budigalimab, ABBV-382 - Human Immuno-deficiency Virus (HIV) Disease	Phase 2	Terminated	AbbVie	163	2023-10-12	2025-10-29
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) Budigalimab, Livmoniplimab, Lenvatinib - Hepatocellular Carcinoma	Phase 2	Active not recruiting	AbbVie	130	2023-09-21	2025-08-14

Conditions studied

Sponsors

Countries

NIH funding